Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers

Clinical Cancer Research

Volumn 19, Issue 14, 2013, Pages 3776-3786

  Prosniak, Michael ^a   Harshyne, Larry A ^a   Andrews, David W ^a   Kenyon, Lawrence C ^a   Bedelbaeva, Kamila ^b   Apanasovich, Tatiyana V ^a   Heber Katz, Ellen ^b   Curtis, Mark T ^a   Cotzia, Paolo ^a   Hooper, D Craig ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD163 ANTIGEN; CD204 ANTIGEN; CD68 ANTIGEN; CELL MARKER; CYTOKINE; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN; PROTEIN M2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; CELL ACTIVITY; CYTOKINE RELEASE; DISCRIMINANT ANALYSIS; FLOW CYTOMETRY; GENE EXPRESSION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOCYTE; NEUTROPHIL; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MALE; MICROGLIA; MIDDLE AGED; NEOPLASM GRADING; PHENOTYPE; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84881151730     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1940     Document Type: Article

References (48)

1. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000;1:459-68.
2. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc 2007;82:1271-86.
3. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. Glioblastoma in adults. Crit Rev Oncol Hematol 2008;67:139-52.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
5. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006;65:529-39.
6. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007;13: 1663-74.
7. Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, Yan H, et al. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 2009;13:701-18.
8. Mangiola A, Maira G, De Bonis P, Porso M, Pettorini B, Sabatino G, et al. Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neurooncol 2006;76:159-63.
9. Yang MY, Zetler PM, Prins RM, Khan-Farooqi H, Liau LM. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. Expert Rev Neurother 2006;6:1481-94.
10. Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev 2008;222:70-100.
11. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006;8:261-79.
12. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto HS, et al. Anti-tumor activity and trafficking of self, tumorspecific T cells against tumors located in the brain. Cancer Immunol Immunother 2008;57: 1279-89.
13. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999;100:216-32.
14. Prins RM, Graf MR, Merchant RE. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol Immunother 2001;50: 285-92.
15. Daga A, Bottino C, Castriconi R, Gangemi R, Ferrini S. New perspectives in glioma immunotherapy. Curr Pharm Des 2011;17:2439-67.
16. de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol 1992;4:314-20.
17. Spits H, de Waal Malefyt R. Functional characterization of human IL-10. Int Arch Allergy Immunol 1992;99:8-15.
18. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, et al. Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep 2006;15: 1513-16.
19. Rolle CE, Sengupta S, Lesniak MS. Mechanisms of immune evasion by gliomas. Adv Exp Med Biol 2012;746:53-6.
20. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, at al. IL-10 elicits IFNg-dependent tumor immune surveillance. Cancer Cell 2011;20:781-6.
21. Segal BM, Glass DD, Shevach EM. Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 2002;168:1-4.
22. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 1997;17:3217-24.
23. Lu L, Ma J, Wang X, Wang J, Zhang F, Yu J, et al. Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+Treg. Eur J Immunol 2010;40:142-2.
24. Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Res 2008;28:1143-50.
25. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, et al. Effector Tcell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-b. Clin Cancer Res 2011;17: 4296-08.
26. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010;12: 351-5.
27. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011;13:591-9.
28. Wagner S, Czub S, Greif M, Vince GH, Süss N, Kerkau S, et al. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer 1999;82:12-16.
29. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 antiinflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008;216:15-24.
30. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002;62:3347-50.
31. Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong LY, Wu A, et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res 2011;17:4642-49.
32. Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 2005;11:5292-99.
33. Fisher RA. The use of multiple measurements in taxonomic problems. Ann Eugen 1936;2:179-88.
34. Hastie T, Tibshirani R. Discriminant analysis by Gaussian mixtures. J R Stat Soc Ser B 1996;58:155.
35. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, et al. The role of 2 FOXP3 isoforms in the generation of human CD4+Tregs. J Clin Invest 2005;115:3276-84.
36. Nitta T, HishiiM, Sato K, Okumura K. Selective expression of interleukin- 10 gene within glioblastoma multiforme. Brain Res 1994;649:122-8.
37. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al. Gliomaassociated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010;16:461-73.
38. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000;89:251-8.
39. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, et al. Incidence and prognostic impact of FoxP3+regulatory T cells in human gliomas. Clin Cancer Res 2008;14:5166-72.
40. Qiu B, Zhang D, Wang C, Tao J, Tie X, Qiao Y, et al. IL-10 and TGF-b2 are overexpressed in tumor spheres cultured from human gliomas. Mol Biol Rep 2011;38:3585-91.
41. Moulding HD, Friedman DP, Curtis M, Kenyon L, Flanders AE, Paek SH, et al. Revisiting anaplastic astrocytomas I: an expansive growth pattern is associated with a better prognosis. J Magn Reson Imaging 2008;28:1311-21.
42. Itakura E, Huang RR, Wen DR, Paul E, Wünsch PH, Cochran AJ. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 2011;24:801-9.
43. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 2007;30:627-32.
44. Nacinovic-Duletic A, Stifter S, Dvornik S, Skunca Z, Jonjic N. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 2008;30:230-9.
45. Smith KE, Fritzell S, Badn W, Ebersta S, Janelidze S, Visse E, et al. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells. Int J Cancer 2009;124:630-7.
46. Vega EA, Graner MW, Sampson JH. Combating immunosuppression in glioma. Future Oncol 2008;4:433-42.
47. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001;19: 2189-200.
48. Dunn GP, Dunn IF, Curry WT. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 2007; 7:1-16.